NEWS&EVENTS

BACK TO LIST
January 11th 2021 The CARBALIVE Consortium announces positive results of a Phase 2 equivalent trial of engineered macroporous carbons as a novel treatment for cirrhosis The CARBALIVE Consortium is focused on developing a novel treatment for patients with advanced liver disease. It is composed of partners from across Europe, led by University College London, and includes Yaqrit, a life sciences company and the intellectual property owner of Carbalive™ and the European Foundation for the Study of Chronic Liver Failure, among others.

The CARBALIVE Consortium has announced that the Phase 2 clinical trial has obtained positive data on efficacy of Carbalive™, a product candidate for the treatment of patients with decompensated cirrhosis.

The Consortium is developing and testing Carbalive™, an orally-administered, non-absorbable engineered carbon of controlled porosity. Carbalive™ is specifically designed to remove harmful bacterial toxins from the gut, reduce gut inflammation and its permeability, preventing them from leaking into the rest of the body. This academic-industrial consortium has received funding for the project from the European Union's Horizon 2020 research and innovation programme under grant agreement No 634579

Download attached document (745,56 KB)
BACK TO LIST
}